Skip Navigation
Genetics Home Reference: your guide to understanding genetic conditions
http://ghr.nlm.nih.gov/     A service of the U.S. National Library of Medicine®

SLC2A10

Reviewed January 2013

What is the official name of the SLC2A10 gene?

The official name of this gene is “solute carrier family 2 (facilitated glucose transporter), member 10.”

SLC2A10 is the gene's official symbol. The SLC2A10 gene is also known by other names, listed below.

What is the normal function of the SLC2A10 gene?

The SLC2A10 gene provides instructions for making a protein called GLUT10. GLUT10 is classified as a glucose transporter; this type of protein moves the simple sugar glucose across cell membranes and helps maintain proper levels of glucose within cells. However, GLUT10 has some structural differences from other glucose transporters, and its role in the movement of glucose or other substances is unclear.

The level of GLUT10 appears to be involved in the regulation of a process called the transforming growth factor-beta (TGF-β) signaling pathway. This pathway is involved in cell growth and division (proliferation) and the process by which cells mature to carry out special functions (differentiation). The TGF-β signaling pathway is also involved in bone and blood vessel development and the formation of the extracellular matrix, an intricate lattice of proteins and other molecules that forms in the spaces between cells and defines the structure and properties of connective tissues. Connective tissue provides strength and flexibility to structures throughout the body, including blood vessels, skin, joints, and the gastrointestinal tract.

Studies indicate that GLUT10 may also be involved in the functioning of mitochondria, the energy-producing centers within cells.

Does the SLC2A10 gene share characteristics with other genes?

The SLC2A10 gene belongs to a family of genes called SLC (solute carriers).

A gene family is a group of genes that share important characteristics. Classifying individual genes into families helps researchers describe how genes are related to each other. For more information, see What are gene families? (http://ghr.nlm.nih.gov/handbook/howgeneswork/genefamilies) in the Handbook.

How are changes in the SLC2A10 gene related to health conditions?

arterial tortuosity syndrome - caused by mutations in the SLC2A10 gene

At least 19 SLC2A10 gene mutations have been identified in people with arterial tortuosity syndrome, a connective tissue disorder characterized by abnormal curving and twisting (tortuosity) of the blood vessels that carry blood from the heart to the rest of the body (arteries) and other health problems.

The mutations that cause arterial tortuosity syndrome reduce or eliminate GLUT10 function. By mechanisms that are not well understood, a lack (deficiency) of functional GLUT10 protein leads to overactivity (upregulation) of TGF-β signaling. Excessive growth signaling results in elongation of the arteries. Since the end points of the arteries are fixed, the extra length twists and curves, leading to tortuosity. Overactive TGF-β signaling also interferes with normal formation of the connective tissues in other parts of the body, leading to the joint and skin abnormalities and other features of arterial tortuosity syndrome.

Changes in mitochondrial function related to GLUT10 deficiency may also affect cardiovascular system development, but the relationship between mitochondrial function and the specific signs and symptoms of arterial tortuosity syndrome is unclear.

other disorders - course of condition modified by normal variations in the SLC2A10 gene

Several normal variations (polymorphisms) of the SLC2A10 gene have been associated with an increased risk of peripheral artery disease in people with type 2 diabetes, a disorder in which resistance to the hormone insulin leads to excess glucose levels in the blood (hyperglycemia). Peripheral artery disease is a condition in which an accumulation of fatty deposits and scar-like tissue in the lining of the arteries (atherosclerosis) reduces blood flow to the legs, causing pain when walking. Problems with blood vessels, including peripheral artery disease, are common in type 2 diabetes, and are believed to be related to the effect of hyperglycemia on TGF-β signaling. Alterations in the GLUT10 protein caused by SLC2A10 gene variations may also affect TGF-β signaling and increase the risk of blood vessel problems in diabetes.

Where is the SLC2A10 gene located?

Cytogenetic Location: 20q13.1

Molecular Location on chromosome 20: base pairs 46,709,639 to 46,736,346

The SLC2A10 gene is located on the long (q) arm of chromosome 20 at position 13.1.

The SLC2A10 gene is located on the long (q) arm of chromosome 20 at position 13.1.

More precisely, the SLC2A10 gene is located from base pair 46,709,639 to base pair 46,736,346 on chromosome 20.

See How do geneticists indicate the location of a gene? (http://ghr.nlm.nih.gov/handbook/howgeneswork/genelocation) in the Handbook.

Where can I find additional information about SLC2A10?

You and your healthcare professional may find the following resources about SLC2A10 helpful.

You may also be interested in these resources, which are designed for genetics professionals and researchers.

What other names do people use for the SLC2A10 gene or gene products?

  • ATS
  • glucose transporter type 10
  • GLUT10
  • GLUT-10
  • GTR10_HUMAN
  • solute carrier family 2, facilitated glucose transporter member 10

See How are genetic conditions and genes named? (http://ghr.nlm.nih.gov/handbook/mutationsanddisorders/naming) in the Handbook.

What glossary definitions help with understanding SLC2A10?

arteries ; artery ; atherosclerosis ; cardiovascular ; carrier ; cell ; connective tissue ; deficiency ; diabetes ; differentiation ; extracellular ; extracellular matrix ; gastrointestinal ; gene ; glucose ; growth factor ; hormone ; insulin ; joint ; mitochondria ; peripheral ; proliferation ; protein ; simple sugar ; solute ; syndrome ; tissue ; tortuosity

You may find definitions for these and many other terms in the Genetics Home Reference Glossary (http://www.ghr.nlm.nih.gov/glossary).

References

  • Akhurst RJ. A sweet link between TGFbeta and vascular disease? Nat Genet. 2006 Apr;38(4):400-1. (http://www.ncbi.nlm.nih.gov/pubmed/16570059?dopt=Abstract)
  • Callewaert BL, Willaert A, Kerstjens-Frederikse WS, De Backer J, Devriendt K, Albrecht B, Ramos-Arroyo MA, Doco-Fenzy M, Hennekam RC, Pyeritz RE, Krogmann ON, Gillessen-kaesbach G, Wakeling EL, Nik-zainal S, Francannet C, Mauran P, Booth C, Barrow M, Dekens R, Loeys BL, Coucke PJ, De Paepe AM. Arterial tortuosity syndrome: clinical and molecular findings in 12 newly identified families. Hum Mutat. 2008 Jan;29(1):150-8. (http://www.ncbi.nlm.nih.gov/pubmed/17935213?dopt=Abstract)
  • Castori M, Ritelli M, Zoppi N, Molisso L, Chiarelli N, Zaccagna F, Grammatico P, Colombi M. Adult presentation of arterial tortuosity syndrome in a 51-year-old woman with a novel homozygous c.1411+1G>A mutation in the SLC2A10 gene. Am J Med Genet A. 2012 May;158A(5):1164-9. doi: 10.1002/ajmg.a.35266. Epub 2012 Apr 9. (http://www.ncbi.nlm.nih.gov/pubmed/22488877?dopt=Abstract)
  • Coucke PJ, Willaert A, Wessels MW, Callewaert B, Zoppi N, De Backer J, Fox JE, Mancini GM, Kambouris M, Gardella R, Facchetti F, Willems PJ, Forsyth R, Dietz HC, Barlati S, Colombi M, Loeys B, De Paepe A. Mutations in the facilitative glucose transporter GLUT10 alter angiogenesis and cause arterial tortuosity syndrome. Nat Genet. 2006 Apr;38(4):452-7. Epub 2006 Mar 19. (http://www.ncbi.nlm.nih.gov/pubmed/16550171?dopt=Abstract)
  • Jiang YD, Chang YC, Chiu YF, Chang TJ, Li HY, Lin WH, Yuan HY, Chen YT, Chuang LM. SLC2A10 genetic polymorphism predicts development of peripheral arterial disease in patients with type 2 diabetes. SLC2A10 and PAD in type 2 diabetes. BMC Med Genet. 2010 Aug 25;11:126. doi: 10.1186/1471-2350-11-126. (http://www.ncbi.nlm.nih.gov/pubmed/20735855?dopt=Abstract)
  • NCBI Gene (http://www.ncbi.nlm.nih.gov/gene/81031)
  • OMIM: SOLUTE CARRIER FAMILY 2 (FACILITATED GLUCOSE TRANSPORTER), MEMBER 10 (http://omim.org/entry/606145)
  • Ritelli M, Drera B, Vicchio M, Puppini G, Biban P, Pilati M, Prioli MA, Barlati S, Colombi M. Arterial tortuosity syndrome in two Italian paediatric patients. Orphanet J Rare Dis. 2009 Sep 25;4:20. doi: 10.1186/1750-1172-4-20. (http://www.ncbi.nlm.nih.gov/pubmed/19781076?dopt=Abstract)
  • Segade F. Glucose transporter 10 and arterial tortuosity syndrome: the vitamin C connection. FEBS Lett. 2010 Jul 16;584(14):2990-4. doi: 10.1016/j.febslet.2010.06.011. Epub 2010 Jun 12. Review. (http://www.ncbi.nlm.nih.gov/pubmed/20547159?dopt=Abstract)
  • Willaert A, Khatri S, Callewaert BL, Coucke PJ, Crosby SD, Lee JG, Davis EC, Shiva S, Tsang M, De Paepe A, Urban Z. GLUT10 is required for the development of the cardiovascular system and the notochord and connects mitochondrial function to TGFβ signaling. Hum Mol Genet. 2012 Mar 15;21(6):1248-59. doi: 10.1093/hmg/ddr555. Epub 2011 Nov 24. (http://www.ncbi.nlm.nih.gov/pubmed/22116938?dopt=Abstract)

 

The resources on this site should not be used as a substitute for professional medical care or advice. Users seeking information about a personal genetic disease, syndrome, or condition should consult with a qualified healthcare professional. See How can I find a genetics professional in my area? (http://ghr.nlm.nih.gov/handbook/consult/findingprofessional) in the Handbook.

 
Reviewed: January 2013
Published: April 7, 2014